Jobs / United States / Astrazeneca Pharmaceuticals Lp
Global Brand Senior Director - GI Cancer
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Gaithersburg - MD
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles2 certified filings for “Director, Brand Analytics” (Data Scientists) in DE: $205k–$225k, median $215k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
As the Global Brand Director - GI Cancer, you will lead the global commercial strategy for a novel CLDN18.2-targeted antibody-drug conjugate, with the potential to transform outcomes for patients across multiple gastric cancer settings. Building on a strong launch foundation, you will drive global performance, shape future indications and establish the asset as a benchmark for launch excellence across Oncology. You will lead commercial preparation for the CG-02 indication . The role may also offer a flexible China-based development opportunity, potentially for up to six months, to help accelerate GI Asia priorities, strengthen Global-China collaboration and identify best practices from the asset launch and the wider AstraZeneca enterprise that can be scaled across the organization . The scope, timing and format of any assignment would be subject to further assessment of business priorities, practical feasibility and mutual agreement. In this role, you will be part of the Global IO Commercial Franchise Team and will set and implement the global brand strategy for this priority ADC asset. The role leads integrated commercial planning across launch, growth and lifecycle development, working with global, regional and country teams and with Marketing, Global Analytics & Insights, Digital, Diagnostics, Pricing and Market Access, Global Medical Affairs, Clinical Development, Regulatory Affairs, Corporate Affairs and other partners. The role is accountable for creating a differentiated strategy and campaign, generating deep customer and market insights, delivering launch readiness, informing evidence and investment choices, and building market-shaping programs that maximize patient and business impact. It also represents Global Commercial perspectives in relevant cross-functional governance forums. Typical accountabilities: 1. Global brand strategy and leadership • Set and communicate a clear, differentiated and long-term global brand strategy for the asset aligned with the GI tumor strategy and broader Oncology priorities. • Lead annual strategic and operational planning, including positioning, segmentation, customer strategy, value proposition, target market selection and lifecycle priorities. • Generate deep customer, patient, market and competitive insights and translate them into choices that address unmet need and maximize value. • Develop future-focused revenue forecasts and business cases informed by robust insights and sound commercial judgement. • Represent Global Commercial in relevant Global Product Team and investment decision forums, providing commercially rigorous input to evidence generation and Phase III decisions. 2. Launch excellence and market shaping • Lead global launch strategy, launch readiness and execution for the asset across priority markets, with clear milestones, decision points and performance measures. • Develop a novel global brand campaign, clear and impactful messaging, core launch tactics and an integrated customer experience approach. • Build distinctive market-shaping programs that increase understanding of the unmet need, CLDN18.2 testing and the evolving role of ADCs in gastric cancer. • Engage regional and country teams early, incorporate market feedback and establish mechanisms to share learning and accelerate adoption of best practice. • Lead agency and vendor relationships, ensuring quality, pace, compliance, value and effective use of resources. 3. CG-02 indication leadership • Lead commercial preparation for the CG-02 indication as a major future growth opportunity • Define the future market, customer needs, competitive differentiation, positioning, value proposition, and launch approach. • Partner with Clinical Development, Medical,